These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21664100)

  • 1. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.
    Harris KC; Anis AH; Crosby MC; Cender LM; Potts JE; Human DG
    Can J Cardiol; 2011; 27(4):523.e11-5. PubMed ID: 21664100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of palivizumab in children with congenital heart disease in Germany.
    Nuijten M; Lebmeier M; Wittenberg W
    J Med Econ; 2009; 12(4):301-8. PubMed ID: 19811110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.
    Chang RK; Chen AY
    Pediatr Cardiol; 2010 Jan; 31(1):90-5. PubMed ID: 19915892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J
    Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
    Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
    Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.
    Rackham OJ; Thorburn K; Kerr SJ
    Cardiol Young; 2005 Jun; 15(3):251-5. PubMed ID: 15865826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
    Nuijten M; Lebmeier M; Wittenberg W
    J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
    Meberg A; Bruu AL
    Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab in prevention of bronchiolitis: new preparation. Moderate efficacy in some infants.
    Prescrire Int; 2000 Dec; 9(50):171-2, 174. PubMed ID: 11475494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society].
    Chantepie A;
    Arch Pediatr; 2004 Nov; 11(11):1402-5. PubMed ID: 15519844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
    Committee on Infectious Diseases
    Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR; Hoopes JM; Hemming VG
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.